Compare American Tower Corp (AMT) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Tower Corp vs Enveric Biosciences Inc — how do they compare? American Tower Corp trades at $169 (market cap $78.54B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: American Tower Corp is far larger — about 14437.5× Enveric Biosciences Inc's market cap, and American Tower Corp pays a 4.14% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AMT | ENVB | |
|---|---|---|
Market Cap | $78.54B | $5.44M |
Sector | Real Estate | Health |
52-Week High | $232.35 | $17.40 |
52-Week Low | $162.11 | $1.28 |
Enterprise Value | $122.07B | $529.67K |
Dividend Yield | 4.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $168.59, up 2.18% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals including a 26.81% net margin and 82.19% ROE. Recent news highlights its data center growth and sustainability initiatives, while analyst consensus remains strongly bullish with a $214.10 price target.
AMT presents a compelling long-term investment opportunity given its high profitability, dividend yield, and market leadership, though elevated debt levels and near-term technical weakness pose risks. Upside potential exists if the company continues executing on 5G and data center expansion, but investors should monitor interest rate sensitivity and competitive pressures.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
